LEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately.
In her new role, Dr. Ahuja will act as the company’s key medical spokesperson providing leadership and strategic direction for all medical, clinical and scientific affairs activities for T2 Biosystems.
“I am excited to be joining the T2 Biosystems leadership team at this critical time when high-quality rapid diagnostics – especially for sepsis – are growing in importance as we continue to face mounting global health challenges, like managing antimicrobial resistance, rising health care expenses, secondary and co-infections associated with the COVID-19 virus,” said Dr. Ahuja.
Dr. Ahuja possesses extensive global experience in Laboratory Medicine and in the medical device and diagnostics industry. Most recently, she served as Worldwide Vice President, Medical Affairs at Becton Dickinson (NYSE:BDX), a leading global medical technology company. Prior to Becton Dickinson, Dr. Ahuja held a variety of roles in clinical practice, research and academia. She is an active member of the American Association of Clinical Chemistry (AACC), College of American Pathologists (CAP), American Society of Microbiology (ASM), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), and serves as President of AACC New Jersey section and Vice Chairholder of CLSI Expert Panel.
“I am confident that Aparna’s extensive professional experience and passion for improving patient care through diagnostic technology will help to increase awareness and foster adoption of our technology,” said John Sperzel, President and CEO at T2 Biosystems. “She has dedicated the entirety of her career to continuously improving diagnostic and testing capabilities, as well as patient outcomes, which is well-aligned with our mission and our focus on the rapid detection of sepsis-causing pathogens.”
T2 Biosystems is the Company behind the FDA-cleared T2Bacteria® Panel and T2Candida® Panel. These panels are the only FDA-cleared assays for the detection of sepsis-causing bacterial and fungal pathogens directly from whole blood in three to five hours, without the need to wait days for blood culture results. By providing quicker results, the panels enable clinicians to target therapy faster for their patients suspected of sepsis, often before the second dose of antimicrobial is administered, leading to better patient outcomes, improved antimicrobial stewardship, and reductions in length of stay in the hospital.
Last year, the Company received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its COVID-19 molecular diagnostic test, the T2SARS-CoV-2™ Panel. The panel detects SARS-CoV-2, the virus responsible for COVID-19 infections, and provides results in under two hours utilizing a nasopharyngeal swab sample.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2ResistanceTM Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2CaurisTM Panel, and T2Lyme TM Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the ability of the Chief Medical Officer to impact on sepsis management and the adoption of T2 Biosystems’ products, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, or SEC, on March 16, 2020, and other filings the Company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
Gina Kent, Vault Communications
Philip Trip Taylor, Gilmartin Group